David A. Zilberberg

Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 4.250% senior notes…

Davis Polk advised the representatives and joint book-running managers of an SEC-registered offering by Black Hills Corporation of $400 million aggregate principal amount of its 3.050%…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,303,030 shares of its common stock. The common stock is listed on the…

Davis Polk advised the joint lead arranger and bookrunner, and the administrative agent, in connection with a $4 billion unsecured revolving credit facility provided to McKesson Corporation…

Davis Polk advised the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €1.4 billion aggregate principal amount of senior notes in two series, consisting of €750…

Davis Polk advised the joint lead arrangers and joint bookrunners and the administrative agent, in connection with a $2.425 billion senior secured credit facility to II-VI…

Davis Polk advised the initial purchasers in connection with a Rule 144A and Regulation S offering by Spectrum of $300 million aggregate principal amount of its 5.00% senior notes due 2029…

Davis Polk advised the joint bookrunners in connection with an offering by PerkinElmer, Inc. of $850 million aggregate principal amount of its 3.300% notes due 2029. Headquartered in…

Davis Polk acted as counsel to the underwriter, forward seller and forward purchaser in connection with the execution of a forward sale agreement with HL1 17 LP (the “Selling Shareholder”),…

Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera Pharmaceuticals, Inc. of 10,810,810 shares of common stock for gross proceeds…